Staar Surgical downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley downgraded Staar Surgical to Underweight from Equal Weight with a price target of $37, down from $50. The analyst sees risk to the Chinese consumer and says Street expectations for a meaningful growth acceleration in 2025 and 2026 “seem unrealistic at this point.” The firm says that while Staar’s Q2 “is likely fine” and the company’s U.S. traction should continue to build, slower growth estimates in China over the mid-term leave it behind consensus on 2026 sales.